Details for New Drug Application (NDA): 210589
✉ Email this page to a colleague
NDA 210589 describes OMEGAVEN, which is a drug marketed by Fresenius Kabi Usa and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the OMEGAVEN profile page.
The generic ingredient in OMEGAVEN is fish oil triglycerides. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fish oil triglycerides profile page.
The generic ingredient in OMEGAVEN is fish oil triglycerides. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fish oil triglycerides profile page.
Summary for 210589
| Tradename: | OMEGAVEN |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | fish oil triglycerides |
| Patents: | 1 |
Suppliers and Packaging for NDA: 210589
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589 | NDA | Fresenius Kabi USA, LLC | 63323-205 | 63323-205-00 | 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-205-00) / 100 mL in 1 VIAL, SINGLE-DOSE (63323-205-31) |
| OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589 | NDA | Fresenius Kabi USA, LLC | 63323-205 | 63323-205-50 | 10 VIAL, SINGLE-DOSE in 1 CARTON (63323-205-50) / 50 mL in 1 VIAL, SINGLE-DOSE (63323-205-21) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | EMULSION;INTRAVENOUS | Strength | 5GM/50ML (0.1GM/ML) | ||||
| Approval Date: | Jul 27, 2018 | TE: | RLD: | Yes | |||||
| Patent: | 9,566,260 | Patent Expiration: | Jul 30, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12 | ||||||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | EMULSION;INTRAVENOUS | Strength | 10GM/100ML (0.1GM/ML) | ||||
| Approval Date: | Jul 27, 2018 | TE: | RLD: | Yes | |||||
| Patent: | 9,566,260 | Patent Expiration: | Jul 30, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patented Use: | TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12 | ||||||||
Expired US Patents for NDA 210589
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589-002 | Jul 27, 2018 | 9,629,821 | ⤷ Start Trial |
| Fresenius Kabi Usa | OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589-001 | Jul 27, 2018 | 10,350,186 | ⤷ Start Trial |
| Fresenius Kabi Usa | OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589-001 | Jul 27, 2018 | 9,629,821 | ⤷ Start Trial |
| Fresenius Kabi Usa | OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589-002 | Jul 27, 2018 | 10,350,186 | ⤷ Start Trial |
| Fresenius Kabi Usa | OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589-001 | Jul 27, 2018 | 9,566,260 | ⤷ Start Trial |
| Fresenius Kabi Usa | OMEGAVEN | fish oil triglycerides | EMULSION;INTRAVENOUS | 210589-002 | Jul 27, 2018 | 9,566,260 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
